Background. Fine-needle aspiration biopsy (FNAB) of the thyroid categorized as atypia of undetermined significance/follicular lesion of undetermined significance (AUS/ FLUS) is a newly defined category according to the recent Bethesda guidelines. We sought to assess the characteristics and treatment of patients with an AUS/FLUS FNAB at our institution. Additionally, we evaluated the utility of the recommended 3-month timing of repeat FNAB. Methods. A retrospective study of all patients with an FNAB categorized as AUS/FLUS at an academic tertiarycare center. Clinical, cytological, and ultrasound variables were compared among management groups. Differences in patients receiving repeat FNAB before or after a 3-month interval were compared. Results. A total of 203 patients of the 5,391 FNABs performed at our institution met the Bethesda criteria for AUS/ FLUS; 62 % were sent directly to surgery, 25 % had a repeat FNAB, and 13 % were observed. Younger (p = 0.006) and male patients (p = 0.04) were more likely to go directly to surgery. Microcalcifications, irregular margins, and marked hypoechogenicity on ultrasound did not appear to influence the decision to repeat the FNAB, observe the patient, or refer the patient for surgery. Timing of repeat FNAB (\3 months or C3 months) did not alter the diagnostic results of the second FNAB (p = 0.73). The overall rate of malignancy in patients undergoing surgery was 15.7 %. Conclusions. Gender and age, not ultrasound characteristics, appear to influence the decision for surgery in AUS/ FLUS patients. Timing of repeat biopsy did not alter management, repeat FNAB diagnosis, or rate of malignancy in our cohort.
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Most thyroid nodules are benign. Fine-needle aspiration biopsy (FNAB) is the gold standard for the evaluation of thyroid nodules, and this procedure plays a key role in disease management. 1 Classification and reporting systems for thyroid FNAB results are not standardized across, and often within, institutions. 2, 3 A revised classification system for reporting thyroid FNAB cytology was proposed at the National Cancer Institute State of Science conference (NCISSC) in 2007. 2 This led to the Bethesda System for Reporting Thyroid Cytopathology (BS), which provides a revised six-tiered reporting system with an emphasis on the risk of malignancy associated with each category (Table 1) . 4 The category ''indeterminate for malignancy'' was subdivided into ''suspicious for malignancy,'' ''follicular neoplasm,'' and ''atypia of undetermined significance/follicular lesion of undetermined significance'' (AUS/FLUS) on the basis of morphology, cytology, and corresponding risk of malignancy, allowing further stratification of lesions with a follicular pattern, with or without nuclear atypia.
The category AUS/FLUS is heterogeneous: specimens placed in this category cannot be characterized as benign as a result of the presence of follicular cells with nuclear or architectural atypia, yet the atypia is insufficient for categorization as suspicious for malignancy, malignant, or follicular neoplasm. The risk of malignancy for an AUS/FLUS FNAB continues to be studied; however, the estimated reported risk is 5-19 % of those referred for surgery. [4] [5] [6] [7] The overall risk of malignancy will be higher when the denominator is based on patients referred for surgery and lower when the denominator consists of all diagnosed patients. 8 As per the synopsis of the NCISSC, patients with an AUS/FLUS FNAB should undergo a second FNAB after 3 months on the basis of clinical correlation and/or ultrasound findings. 4, 7, 9, 10 Performing a repeat FNAB before 3 months is thought to increase the chance of reparative atypia of follicular cells, with the potential for false-positive diagnosis of malignancy. 2 However, there is little objective information to support this recommendation.
Although the BS thyroid FNAB cytopathology classification is new, a similar system has been in use at our institution for the last 15 years. We hoped to use the data from our experience with this category to guide others new to using this scheme. The aim of our study was to determine how patients with AUS/FLUS results were treated at our institution and whether they were in fact always undergoing a repeat FNAB after the recommended waiting period of 3 months. Our hypothesis was that waiting 3 months to repeat the FNAB in patients with an initial diagnosis of AUS/FLUS is not necessary. We reviewed the treatment of patients at our institution with AUS/FLUS FNABs. We determined whether various clinical, morphological, and ultrasound characteristics, or whether the timing of the repeat biopsy played a role in directing the next step in this new category of patients.
METHODS

Patient Cohort
An institutional review board-approved search of the Massachusetts General Hospital cytology electronic database was performed for January 2005 through December 2007. During this time, a total of 5,391 thyroid FNABs were performed; 254 patients had their FNAB interpreted as AUS/FLUS (4.7 %), as defined by the BS proposed by the National Cancer Institute, and included FNABs interpreted as ''atypical,'' ''atypia of undetermined significance,'' ''follicular lesion of undetermined significance,'' and ''rule out follicular neoplasm.'' 2,4,10 For each patient, additional fine-print notes provided in the text of the report were also reviewed by our cytopathologist (W.C.F.). Fiftyone patients were excluded for lack of adequate follow-up.
Of the 203 remaining patients, 162 were female (80 %) and had a mean ± SD age of 53 ± 13 years. We divided our cohort into three groups according to the next management step after initial AUS/FLUS FNAB (Fig. 1) , as follows: group 1: patients referred directly for surgery without a repeat FNAB; group 2: patients with a repeat FNAB at any time after initial FNAB; subgroup 2a: FNAB performed \3 months after initial FNAB; subgroup 2b: FNAB performed C3 months after initial FNAB; and group 3: patients who received only observation after the initial AUS/FLUS FNAB. In this category, adequate follow-up was defined as at least one 6-month follow-up endocrinology visit with ultrasound.
Each group or subgroup was compared on the basis of the following: (1) demographic and clinical characteristics: age, gender, history of radiation, presence or absence of Hashimoto thyroiditis, previous thyroid surgery, thyroidstimulating hormone (TSH) levels, and family history of thyroid disease; (2) ultrasound characteristics (echogenicity, margins, size, microcalcifications, and central flow), and (3) final pathology. On final pathology, only the index nodule was considered as benign or malignant. Patients with papillary microcarcinomas were not considered to have malignant thyroid disease unless the index nodule with AUS/FLUS was malignant.
The FNABs were performed under ultrasound guidance using three to four passes with 25-27-gauge needles. Six to eight alcohol-fixed smears underwent Papanicolaou staining, while the remainder was prepared for ThinPrep by rinsing the needle in Cytolyte. 7 All cytology reports and slides were reviewed again by one cytopathologist (W.C.F.) and were found to be concordant with the original reading.
Statistical Analysis
Univariate analysis by Pearson v 2 test for discrete variables and analysis of variance for continuous variables were performed to determine statistical significance. A p-value of \0.05 was considered significant.
RESULTS
Patients Referred for Repeat FNAB or Directly to Surgery Have Similar Rates of Malignancy on Final Pathology
Of 203 patients in our cohort with AUS/FLUS on initial FNAB, 125 patients (62 %) were in group 1 (referred directly to surgery), 51 patients (25 %) were in group 2 (repeat FNAB), and 27 patients (13 %) were in group 3 (observed). Table 2 lists the data analysis for these groups. When the three groups were compared for demographic and clinical characteristics, patients in group 1 were significantly younger and were more likely to be male compared to the other groups. All other clinical and ultrasound imaging characteristics (history of radiation, presence or absence of Hashimoto thyroiditis, previous thyroid surgery, TSH levels, family history of thyroid disease, echogenicity, nodule margins, nodule size, presence of microcalcifications, and central flow) were not statistically different among groups.
Group 1 All 125 patients in group 1 were referred directly to surgery after the initial FNAB revealed AUS/ FLUS. A total of 105 patients (84 %) had a benign diagnosis on final pathology. Twenty patients (16 %) had a malignancy: classical papillary thyroid cancer was observed in ten patients, follicular variant of papillary cancer (FVPTC) in four, minimally invasive follicular carcinomas in five, and Hürthle cell carcinoma in one.
Group 2 All 51 patients in group 2 underwent repeat FNAB. The repeat FNAB was benign in 22 patients (43 %) and again read as AUS/FLUS in 17 patients (33 %) patients; six patients (12 %) had nondiagnostic specimens, and three patients each were diagnosed as follicular neoplasm and suspicious for malignancy. Surgery after a repeat biopsy was performed in 26 (51 %) of 51 patients, while 18 patients (35 %) were then observed. Seven patients (14 %) were lost to follow-up after the repeat biopsy. The 18 patients who were initially observed after the second biopsy had a median follow-up of 47 months (21-85 months): three patients had an increase in the size of the index nodule with repeat FNAB with or without core biopsy, which were benign, and one of these three underwent total thyroidectomy with a benign adenoma on final pathology; 14 had stable-sized nodules on ultrasound; and one patient received radioactive iodine for a functioning nodule. In patients subjected to repeat FNAB before surgical intervention, final pathology showed malignancy in four patients (15 %) (two FVPTC and two minimally invasive follicular carcinomas), while the remaining 22 (85 %) had benign thyroid disease ( Table 3 ). The rate of malignancy on final pathology was not statistically different in this group when compared to those directed to surgery without repeat FNAB (group 1).
Group 3 All 27 patients in group 3 were observed and were not subjected to surgery or repeat FNAB within at least a 6-month follow-up. In this group, median follow-up was 48 months (range 7-82 months). Seventeen of the 27 patients had a documented follow-up ultrasound by a primary care provider or endocrinologist showing a stable size (n = 15) or decrease (n = 2) in the size of their nodule. Four patients had significant growth of the nodule on ultrasound, and repeat FNAB showed benign macrofollicular cytology; none of these four patients had thyroid surgery at between 36 and 72 months after their original FNAB showed atypia. Five of the 27 patients had a repeat FNAB performed on the index nodule, and two had FNABs performed on other nodules during their follow-up, all of which had benign cytology. Only two of these 27 patients were seen by a surgeon; one underwent total thyroidectomy with benign pathology at 61 months, and one refused surgery and was lost to follow-up after 7 months. Two of the patients in this category died of other causes (colon cancer and heart failure). Two patients were subsequently diagnosed with thyroiditis, and one patient underwent radioactive iodine therapy for hyperthyroidism.
A 3-Month Waiting Period Before Any Repeat FNAB Does Not Improve the Diagnostic Yield or Alter Patient Care Algorithm
Of those group 2 patients who had repeat FNAB, 30 patients had their repeat FNAB within 3 months of the initial biopsy (early repeat FNAB \ 3 months), while 21 patients had a late repeat FNAB (C 3 months). The median number of days between initial and repeat FNAB for patients who had an early repeat FNAB was 27 days. All five patients with a history of radiation exposure or therapeutic radiation had an early repeat FNAB. In these two subgroups, demographic and ultrasound data showed no statistically significant difference except in those with a history of therapeutic radiation exposure, who were more likely to undergo repeat biopsy within 3 months of initial biopsy (p \ 0.05). None of the other factors-age, gender, morphological pattern on the initial AUS/FLUS, FNAB diagnosis of a second nodule, Hashimoto thyroiditis, ultrasound characteristics of the nodule such as size, central flow, microcalcifications, and cystic nature-were significant in determining whether a repeat biopsy was performed before or after 3 months.
The timing of the repeat biopsy did not significantly alter the distribution of biopsy results (p = 0.73). As shown in Table 4 , patients who underwent biopsies within 3 months of the initial biopsy did not have a significantly increased rate of nondiagnostic or AUS/FLUS in their second biopsy findings compared to those who underwent repeat biopsies after 3 months. In fact, none of the repeat FNABs resulted in a diagnosis of malignancy. Nineteen of 30 patients undergoing FNAB before 3 months underwent surgery; the final pathology was malignant in two and benign in 17 (90 %). In the late repeat FNAB subgroup, seven of 21 patients were referred for surgery after a repeat biopsy; this was not statistically different from those patients who had their repeat biopsy performed before 3 months. In all patients undergoing surgery after late repeat FNAB, final pathology was malignant in only one patient (14 %) and benign in six patients (86 %).
DISCUSSION
In general, the recommendation for management of patients with AUS/FLUS is to perform a repeat FNAB 3 months or more after the initial FNAB. 2, 10 In our retrospective study, we analyzed our institutional experience in management of patients with FNAB's reported as AUS/ FLUS; many of these patients were evaluated before the publication of the NCISSC in 2007 because our institution has used a similarly tiered system for 15 years. 3 We evaluated several possible variables that may have influenced the subsequent management of these patients and determined whether all patients had a repeat FNAB as recommended. We also evaluated whether it was necessary to wait 3 months before repeating the FNAB.
Although the BS advocates the creation of a category termed AUS/FLUS, it also recommends that this category be used sparingly, noting prevalence rates of less than 7 %; higher rates may represent overuse of this category. Most series report that 3-6 % of FNABs performed fall into the AUS/FLUS category. 4, 5, [10] [11] [12] However, a review of data from three university hospitals and found that the prevalence of AUS/FLUS varied 2.5-28.6 % among pathologists and 3.3-14.9 % among institutions. In our series, we found FNAB fine-needle aspiration biopsy, AUS/FLUS atypia of undetermined significance/follicular lesion of undetermined significance a Categories in which malignancy was found on final pathology the prevalence of AUS/FLUS to be approximately 5 %. In our study, more than half of the patients were referred directly for surgery without a repeat FNAB; these patients were more likely to be younger and male than patients who had a repeat FNAB. The BS recommendations also note that certain patients may be sent directly for surgery or be observed without a repeat FNAB on the basis of certain clinical and ultrasound features. 4 It is well established that certain ultrasound characteristics of the nodule, such as size, central flow, and microcalcifications, have been associated with malignancy in other studies; however, in our study, ultrasound features such as microcalcifications, irregular margins, and marked hypoechogenicity did not appear to influence the decision to repeat the FNAB, observe the patient, or refer the patient for surgery. 13, 14 Additional variables such as a family history of thyroid disease, presence of Hashimoto thyroiditis, serum TSH concentration, or history of head or neck irradiation also did not appear to influence this decision. The choice of surgery versus repeat FNAB or observation was primarily based on the patient's age, the patient's gender, the clinical judgment of the endocrinologist and/or surgeon, and patient preference.
The cytoarchitecture of the specimen also appears to have played a role in referring patients directly for surgery. When ''microfollicles'' was written in the fine print of the cytology report, more patients were referred to surgery than when ''macrofollicles'' was used. Aspirates with microfollicles in a background of scant colloid and sparse or low cellularity were also more likely to result in surgery without a second FNAB. These two patterns of cytoarchitecture are both consistent with the description of specimens placed in the AUS/FLUS category. 4 The BS describes specimens with adequate cellularity and a mixed pattern with a relative predominance of microfollicles compared to macrofollicles as AUS/FLUS. This is also true for specimens with low cellularity and scant colloid that have a relative predominance of microfollicles. In both of these scenarios, the cytoarchitectural pattern with a slight increase of microfollicles is insufficient to interpret as suspicious for a follicular neoplasm. 4 However, on the basis of our data, it may be worrisome enough for the clinician to refer patients directly for surgery.
The BS is designed to provide a uniform reporting system for FNAB, with an implied risk of malignancy associated with each diagnostic category. The reported risk of malignancy for AUS/FLUS ranges 5-19 % of patients who have surgery. However, there are serious limitations to this risk assessment. The percentage of AUS/FLUS patients who undergo surgery is often lower than other more suspicious FNAB categories. Usually surgery is only performed in patients deemed to be at a high risk for malignancy or those who have had a second AUS/FLUS biopsy. The risk of malignancy in this category therefore varies depending on whether the denominator is the population undergoing surgery or the entire initial AUS/FLUS group. 4, 8 In our study, almost 75 % of the patients of our 203 patients had surgery, either with or without a repeat FNAB. The overall malignancy rate in our cohort was 15.7 %. This rate of malignancy is consistent with the risk of malignancy reported for AUS/FLUS in other studies. 4 In our series, the risk of malignancy was similar in those patients referred directly for surgery (16 %) and those who had surgery after a repeat FNAB (15 %). Therefore, referring patients for surgery on the basis of clinical characteristics such as age and gender may help identify patients who need surgery almost as well as a repeat biopsy.
In our series, half of the AUS/FLUS patients who went directly to surgery had conventional papillary thyroid carcinoma. The remainder had FVPTC (20 %) or follicular or oxyphilic follicular thyroid carcinomas (30 %). Of the four malignancies found after repeat FNAB, two were FVPTC and two were follicular thyroid carcinomas. Three out of four of these patients had repeat FNAB diagnosed as AUS/ FLUS. When the initial diagnosis on FNAB is AUS/FLUS, a repeat FNAB may help clarify the situation. For example, Yassa et al. reported that a repeat FNAB yielded a benign diagnosis in 50 % of patients, a more suspicious diagnosis in 32 % of patients, and AUS/FLUS in approximately 20 %. 11 In our study, we found that approximately 33 % of patients had an AUS/FLUS diagnosis on repeat biopsy, with almost all of these patients being referred for surgery.
It is recommended that one wait 3 months or more before repeating an FNAB after an initial FNAB categorized as AUS/FLUS. 2, 10 This waiting period is designed to avoid any atypical reparative changes that may interfere with the interpretation of the repeat biopsy and lead to an increased diagnosis of malignancy or suspicious for malignancy. 2 However, there are few data to support this recommendation. We found no statistically significant difference in diagnostic outcome when FNAB was performed less than or more than 3 months after the initial AUS/FLUS FNAB. Specifically, we did not find a difference in the number of biopsies whose results were suggestive of a malignant diagnosis. We also found that the proportion of specimens diagnosed as AUS/FLUS on a repeat biopsy was not significantly increased in patients who had undergone a biopsy at less than 3 months. Therefore, we interpret these retrospective data as evidence that the timing of a repeat FNAB may not be of clinical importance. The timing of the repeat FNAB did not correlate with usual worrisome clinical or ultrasound characteristics but was more likely to be performed at \3 months for patients with a history of head or neck irradiation.
Our study has several limitations. This was a retrospective study, with 51 patients excluded as a result of inadequate follow-up and with 25 patients who underwent repeat FNAB but who did not have surgery, and thus we are missing final pathologic correlation. We were unable to account for the variable of patient preference-a major determinant in clinical practice that might bias management decisions. The AUS/FLUS category is by its nature heterogeneous. Accurate division of specimens into groups on the basis of cytomorphologic architecture or degree of atypia is difficult because the exact number of microfollicles and macrofollicles is not always stated, and classification is subject to the skill, experience, and preferences of the cytopathologist. Although we minimized this variable by having one cytopathologist (W.C.F.) rereview all cytology reports again, this may bias or alter the ultimate usefulness of this study to the general population. In the future, molecular markers may help further guide management. 15, 16 Although current molecular platforms have a very high specificity, specimens negative for a genetic alteration may still be malignant, and repeat biopsy may be useful in identifying these malignancies. 16 On the basis of our study, after an initial FNAB categorized as AUS/FLUS, clinical variables such as age and gender may help the clinician decide between surgery, repeat biopsy, or observation alone. If a decision is made to repeat the FNAB, the repeat FNAB may be performed without a 3-month wait.
